Efficacy Evaluation of Pitaya Ovule Extract on Skin
- Conditions
- Skin Condition
- Interventions
- Dietary Supplement: Placebo drinkDietary Supplement: Pitaya Ovule Extract Drink
- Registration Number
- NCT05311020
- Lead Sponsor
- TCI Co., Ltd.
- Brief Summary
To assess the efficacy of Pitaya Ovule Extract on skin
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- 20 to 65-year-old males or females
- Received medical cosmetic treatment (including cosmetic skin care, laser, fruit acid peeling, injection or plastic surgery, etc.) currently or within one month before the trial
- Outdoor workers (exposed to the sun more than 5 hours a day)
- People who are breastfeeding, pregnant or planning to become pregnant during the test (self-report)
- People with heart, liver, kidney, endocrine and other major organic diseases (self-reported)
- People who have undergone major surgery (according to medical history)
- People who take drugs for a long time
- People with mental illness
- Students who are currently taking courses taught by the principal investigator of this trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo drink Placebo drink - Pitaya Ovule Extract Drink Pitaya Ovule Extract Drink -
- Primary Outcome Measures
Name Time Method The change of skin elasticity Change from Baseline skin elasticity at 8 weeks Cutometer® Dual MPA580 was utilized to measure skin elasticity. Units: arbitrary units
The change of skin pores Change from Baseline skin pores at 8 weeks IRV skin analyzer was utilized to measure skin pores. Units: arbitrary units
The change of skin texture Change from Baseline skin texture at 8 weeks IRV skin analyzer was utilized to measure skin texture. Units: arbitrary units
The change of skin tone Change from Baseline skin tone at 8 weeks IRV skin analyzer was utilized to measure skin tone. Units: arbitrary units
The change of Advanced glycation end products of blood Change from Baseline AGEs at 8 weeks Venous blood was sampled to measure AGEs
The change of Matrix metalloproteinases (MMP-2, MMP-9) of blood Change from Baseline MMPs at 8 weeks Venous blood was sampled to measure MMPs
The change of L* (lightness) values Change from Baseline L* value at 8 weeks Spectrophotometer SCM-108 was utilized to measure skin L\* value. Units: arbitrary units
The change of skin collagen density Change from Baseline skin collagen density at 8 weeks DermaLab® Combo Ultrasound module was utilized to measure skin collagen density. Units: arbitrary units
The change of skin wrinkles Change from Baseline skin wrinkles at 8 weeks IRV skin analyzer was utilized to measure skin wrinkles. Units: arbitrary units
The change of RAGE (receptor for advanced glycation end products) of blood Change from Baseline RAGE at 8 weeks Venous blood was sampled to measure RAGE
- Secondary Outcome Measures
Name Time Method Change from Baseline insulin level at 8 weeks Change from Baseline insulin level at 8 weeks Venous blood was sampled to measure insulin level
The change of liver function biomarkers (AST, ALT) of blood Change from Baseline liver function biomarkers at 8 weeks Venous blood was sampled to measure liver function biomarkers
The change of blood lipid profile Change from Baseline blood lipid profile at 8 weeks Venous blood was sampled to measure blood lipid profile (total cholesterol, HDL-C, LDL-C, triglyceride)
The change of fasting blood glucose level Change from Baseline fasting blood glucose level at 8 weeks Venous blood was sampled to measure fasting blood glucose level
The change of renal function biomarkers (creatinine, BUN) of blood Change from Baseline renal function biomarkers at 8 weeks Venous blood was sampled to measure renal function biomarkers
Trial Locations
- Locations (1)
China Medical University
🇨🇳Taichung, Taiwan